DNA methylation is an important modification in long-term memory function,
33 and the conversion of cytosine bases to 5mC is catalyzed by Dnmts.
18 Among the Dnmt family, Dnmt1 is highly expressed in neuronal cells, and is implicated in neurodegenerative diseases, including Alzheimer's disease.
34 Although Dnmt3a and 3b are de novo enzymes, Dnmt1 has a critical role in maintaining tissue-specific patterns of methylated cytosine.
35,36 In diabetes, Dnmt enzyme activity is increased in the retina and its capillary cells
20; and the expression of Dnmt1 (protein and gene), but not of Dnmt3a or 3b, is also significantly elevated.
21 Here, our results show that Dnmt1 continues to be overexpressed even after termination of hyperglycemia, suggesting its role in the metabolic memory phenomenon. Consistent with our results, differential DNA methylation patterns are observed in the blood samples of patients with proliferative diabetic retinopathy,
37 DNA methylation of
POLG resists arrest.
16 Furthermore, epigenomic profiling of the cells from subsets of DCCT/EDIC participants have clearly documented a significant role of epigenetics in the metabolic memory associated with further progression of complications during EDIC,
38 and recent study has shown that differences in DNA methylation during the DCCT persist at certain loci associated with glycemia for several years during the EDIC study, further supporting the role of epigenetics in the metabolic memory phenomenon.
39 However, a transient “reverse memory” effect, with worsening of retinopathy, during initial stages of tight glycemic control is also observed at times in some diabetic patients. The mechanism responsible for this “reverse memory” is unclear, and the role of epigenetic modifications in such phenomenon remains to be explored.